1. Home
  2. RNXT vs POM Comparison

RNXT vs POM Comparison

Compare RNXT & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenovoRx Inc.

RNXT

RenovoRx Inc.

HOLD

Current Price

$0.93

Market Cap

37.4M

Sector

Health Care

ML Signal

HOLD

POM

POMDOCTOR LIMITED American Depositary Shares

N/A

Current Price

$0.25

Market Cap

30.3M

ML Signal

N/A

Company Overview

Basic Information
Metric
RNXT
POM
Founded
2012
2015
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
37.4M
30.3M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
RNXT
POM
Price
$0.93
$0.25
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$7.75
N/A
AVG Volume (30 Days)
191.9K
476.3K
Earning Date
03-30-2026
12-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$928,000.00
$51,210,721.00
Revenue This Year
$2,795.35
N/A
Revenue Next Year
$272.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.13
52 Week Low
$0.70
$0.21
52 Week High
$1.45
$6.43

Technical Indicators

Market Signals
Indicator
RNXT
POM
Relative Strength Index (RSI) 44.01 27.86
Support Level $0.92 $0.22
Resistance Level $1.08 $0.25
Average True Range (ATR) 0.07 0.02
MACD -0.01 0.06
Stochastic Oscillator 23.81 40.91

Price Performance

Historical Comparison
RNXT
POM

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.

Share on Social Networks: